Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases

Impact · against what's priced in

Annexon presents a binary risk profile where promising Phase III data is offset by significant U.S. regulatory hurdles. The potential for a differentiating product in the geographic atrophy market provides long-term optionality, but immediate valuation depends on resolving dose-response and trial site concerns.

ANNX+0.35

No priced-in read yet